Orange Grove Bio
CEO: Mark Appel
Orange Grove Bio (“OGB”) is a preclinical drug investment and development platform focused on driving down the cost of drug discovery and advancing therapies into clinical trials.
They are partnered with leading universities to license transformational medicines, and to streamline the licensing process, in order to speed up the drug development process and save time on-patent.
Orange Grove Bio's experienced development team works to commercialize promising biomedical research which is located outside of the venture capital hubs of Boston and the Bay Area